{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:04Z","timestamp":1789609204298,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T00:00:00Z","timestamp":1391126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10072-014-1637-4","type":"journal-article","created":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T21:03:39Z","timestamp":1391202219000},"page":"515-520","source":"Crossref","is-referenced-by-count":19,"title":["Italian recommendations for Lambert\u2013Eaton myasthenic syndrome (LEMS) management"],"prefix":"10.1007","volume":"35","author":[{"given":"A.","family":"Evoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Di Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Giometto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Vigliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,31]]},"reference":[{"issue":"5","key":"1637_CR1","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1212\/WNL.59.5.764","volume":"59","author":"F Graus","year":"2002","unstructured":"Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A (2002) P\/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 59(5):764\u2013766","journal-title":"Neurology"},{"key":"1637_CR2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/med\/9780199738670.003.0007","volume-title":"Myasthenia gravis and myasthenic disorders","author":"VC Juel","year":"2012","unstructured":"Juel VC, Sanders DB (2012) The Lambert\u2013Eaton myasthenic syndrome. In: Engel AG (ed) Myasthenia gravis and myasthenic disorders, 2nd edn. Oxford University Press, Oxford, pp 156\u2013169","edition":"2"},{"issue":"6039","key":"1637_CR3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/317737a0","volume":"317","author":"A Roberts","year":"1985","unstructured":"Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J (1985) Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 317(6039):737\u2013739","journal-title":"Nature"},{"key":"1637_CR4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1749-6632.2012.06772.x","volume":"1275","author":"AF Lipka","year":"2012","unstructured":"Lipka AF, Verschuuren JJ, Titulaer MJ (2012) SOX1 antibodies in Lambert\u2013Eaton myasthenic syndrome and screening for small cell lung carcinoma. Ann N Y Acad Sci 1275:70\u201377. doi: 10.1111\/j.1749-6632.2012.06772.x","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"1637_CR5","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","volume":"10","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Lang B, Verschuuren JJ (2011) Lambert\u2013Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 10(12):1098\u20131107. doi: 10.1016\/S1474-4422(11)70245-9","journal-title":"Lancet Neurol"},{"issue":"6","key":"1637_CR6","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","volume":"250","author":"PW Wirtz","year":"2003","unstructured":"Wirtz PW, Nijnuis MG, Sotodeh M, Willems LN, Brahim JJ, Putter H, Wintzen AR, Verschuuren JJ (2003) The epidemiology of myasthenia gravis, Lambert\u2013Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 250(6):698\u2013701. doi: 10.1007\/s00415-003-1063-7","journal-title":"J Neurol"},{"key":"1637_CR7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jneuroim.2008.05.025","volume":"201\u2013202","author":"MJ Titulaer","year":"2008","unstructured":"Titulaer MJ, Wirtz PW, Kuks JB, Schelhaas HJ, van der Kooi AJ, Faber CG, van der Pol WL, de Visser M, Sillevis Smitt PA, Verschuuren JJ (2008) The Lambert\u2013Eaton myasthenic syndrome 1988\u20132008: a clinical picture in 97 patients. J Neuroimmunol 201\u2013202:153\u2013158. doi: 10.1016\/j.jneuroim.2008.05.025","journal-title":"J Neuroimmunol"},{"issue":"Pt 3","key":"1637_CR8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","volume":"111","author":"JH O\u2019Neill","year":"1988","unstructured":"O\u2019Neill JH, Murray NM, Newsom-Davis J (1988) The Lambert\u2013Eaton myasthenic syndrome. A review of 50 cases. Brain 111(Pt 3):577\u2013596","journal-title":"Brain"},{"issue":"Suppl 1","key":"1637_CR9","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1002\/ana.410370708","volume":"37","author":"DB Sanders","year":"1995","unstructured":"Sanders DB (1995) Lambert\u2013Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 37(Suppl 1):S63\u2013S73","journal-title":"Ann Neurol"},{"issue":"4","key":"1637_CR10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0303-8467(02)00054-9","volume":"104","author":"PW Wirtz","year":"2002","unstructured":"Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ (2002) Differences in clinical features between the Lambert\u2013Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg 104(4):359\u2013363","journal-title":"Clin Neurol Neurosurg"},{"issue":"7","key":"1637_CR11","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.59.7.1085","volume":"59","author":"Z Odabasi","year":"2002","unstructured":"Odabasi Z, Demirci M, Kim DS, Lee DK, Ryan HF, Claussen GC, Tseng A, Oh SJ (2002) Postexercise facilitation of reflexes is not common in Lambert\u2013Eaton myasthenic syndrome. Neurology 59(7):1085\u20131087","journal-title":"Neurology"},{"issue":"21","key":"1637_CR12","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000264798.56174.df","volume":"68","author":"SA Rudnicki","year":"2007","unstructured":"Rudnicki SA (2007) Lambert\u2013Eaton myasthenic syndrome with pure ocular weakness. Neurology 68(21):1863\u20131864. doi: 10.1212\/01.wnl.0000264798.56174.df","journal-title":"Neurology"},{"issue":"2","key":"1637_CR13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/jnnp.65.2.213","volume":"65","author":"P Maddison","year":"1998","unstructured":"Maddison P, Newsom-Davis J, Mills KR (1998) Distribution of electrophysiological abnormality in Lambert\u2013Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 65(2):213\u2013217","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1637_CR14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.20389","volume":"32","author":"SJ Oh","year":"2005","unstructured":"Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr (2005) Electrophysiological diagnostic criteria of Lambert\u2013Eaton myasthenic syndrome. Muscle Nerve 32(4):515\u2013520. doi: 10.1002\/mus.20389","journal-title":"Muscle Nerve"},{"issue":"9","key":"1637_CR15","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1207::AID-MUS26>3.0.CO;2-O","volume":"20","author":"M LoMonaco","year":"1997","unstructured":"LoMonaco M, Milone M, Padua L, Tonali P (1997) Combined low-rate nerve stimulation and maximal voluntary contraction in the detection of compound muscle action potential facilitation in Lambert\u2013Eaton myasthenic syndrome. Muscle Nerve 20(9):1207\u20131208","journal-title":"Muscle Nerve"},{"key":"1637_CR16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1749-6632.1998.tb10992.x","volume":"841","author":"B Lang","year":"1998","unstructured":"Lang B, Waterman S, Pinto A, Jones D, Moss F, Boot J, Brust P, Williams M, Stauderman K, Harpold M, Motomura M, Moll JW, Vincent A, Newsom-Davis J (1998) The role of autoantibodies in Lambert\u2013Eaton myasthenic syndrome. Ann N Y Acad Sci 841:596\u2013605","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"1637_CR17","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/01.WNL.0000037485.56217.5F","volume":"59","author":"YK Nakao","year":"2002","unstructured":"Nakao YK, Motomura M, Fukudome T, Fukuda T, Shiraishi H, Yoshimura T, Tsujihata M, Eguchi K (2002) Seronegative Lambert\u2013Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59(11):1773\u20131775","journal-title":"Neurology"},{"issue":"4","key":"1637_CR18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00000441-200004000-00002","volume":"319","author":"M Takamori","year":"2000","unstructured":"Takamori M, Komai K, Iwasa K (2000) Antibodies to calcium channel and synaptotagmin in Lambert\u2013Eaton myasthenic syndrome. Am J Med Sci 319(4):204\u2013208","journal-title":"Am J Med Sci"},{"issue":"11","key":"1637_CR19","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1468-1331.2007.01931.x","volume":"14","author":"M Takamori","year":"2007","unstructured":"Takamori M, Motomura M, Fukudome T, Yoshikawa H (2007) Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders. Eur J Neurol 14(11):1230\u20131235. doi: 10.1111\/j.1468-1331.2007.01931.x","journal-title":"Eur J Neurol"},{"issue":"7","key":"1637_CR20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.autrev.2009.01.015","volume":"8","author":"M Tschernatsch","year":"2009","unstructured":"Tschernatsch M, Gross O, Kneifel N, Kaps M, Blaes F (2009) SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes. Autoimmun Rev 8(7):549\u2013551. doi: 10.1016\/j.autrev.2009.01.015","journal-title":"Autoimmun Rev"},{"issue":"12","key":"1637_CR21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1212\/01.wnl.0000281663.81079.24","volume":"70","author":"L Sabater","year":"2008","unstructured":"Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F (2008) SOX1 antibodies are markers of paraneoplastic Lambert\u2013Eaton myasthenic syndrome. Neurology 70(12):924\u2013928. doi: 10.1212\/01.wnl.0000281663.81079.24","journal-title":"Neurology"},{"issue":"26","key":"1637_CR22","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2008.20.6169","volume":"27","author":"MJ Titulaer","year":"2009","unstructured":"Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, Thijssen PE, Wirtz PW, Twijnstra A, Smitt PA, van der Maarel SM, Verschuuren JJ (2009) SOX antibodies in small-cell lung cancer and Lambert\u2013Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 27(26):4260\u20134267. doi: 10.1200\/JCO.2008.20.6169","journal-title":"J Clin Oncol"},{"key":"1637_CR23","doi-asserted-by":"crossref","unstructured":"Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PA, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJ (2011) Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 18(1):19-e13. doi: 10.1111\/j.1468-1331.2010.03220.x","DOI":"10.1111\/j.1468-1331.2010.03220.x"},{"issue":"7","key":"1637_CR24","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","volume":"29","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, Willcox N, Potman M, Sillevis Smitt PA, Kuks JB, Roep BO, Vincent A, van der Maarel SM, van Dijk JG, Lang B, Verschuuren JJ (2011) Clinical Dutch-English Lambert\u2013Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 29(7):902\u2013908. doi: 10.1200\/JCO.2010.32.0440","journal-title":"J Clin Oncol"},{"issue":"3","key":"1637_CR25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1742395312466903","volume":"9","author":"C Timmermann","year":"2013","unstructured":"Timmermann C (2013) \u2018Just give me the best quality of life questionnaire\u2019: the Karnofsky scale and the history of quality of life measurements in cancer trials. Chronic Illn 9(3):179\u2013190. doi: 10.1177\/1742395312466903","journal-title":"Chronic Illn"},{"key":"1637_CR26","doi-asserted-by":"crossref","unstructured":"Keogh M, Sedehizadeh S, Maddison P (2011) Treatment for Lambert\u2013Eaton myasthenic syndrome. Cochrane Database Syst Rev (2):CD003279. doi: 10.1002\/14651858.CD003279.pub3","DOI":"10.1002\/14651858.CD003279.pub3"},{"key":"1637_CR27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/nyas.12001","volume":"1275","author":"TB Tarr","year":"2012","unstructured":"Tarr TB, Valdomir G, Liang M, Wipf P, Meriney SD (2012) New calcium channel agonists as potential therapeutics in Lambert\u2013Eaton myasthenic syndrome and other neuromuscular diseases. Ann N Y Acad Sci 1275:85\u201391. doi: 10.1111\/nyas.12001","journal-title":"Ann N Y Acad Sci"},{"key":"1637_CR28","doi-asserted-by":"crossref","unstructured":"Maddison P, Newsom-Davis J (2005) Treatment for Lambert\u2013Eaton myasthenic syndrome. Cochrane Database Syst Rev (2):CD003279. doi: 10.1002\/14651858.CD003279.pub2","DOI":"10.1002\/14651858.CD003279.pub2"},{"issue":"6","key":"1637_CR29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","volume":"82","author":"P Maddison","year":"2011","unstructured":"Maddison P, McConville J, Farrugia ME, Davies N, Rose M, Norwood F, Jungbluth H, Robb S, Hilton-Jones D (2011) The use of rituximab in myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 82(6):671\u2013673. doi: 10.1136\/jnnp.2009.197632","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-014-1637-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-014-1637-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-014-1637-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:18:52Z","timestamp":1559121532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-014-1637-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,31]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1007\/s10072-014-1637-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,31]]}}}